Hemal Gada is a Cardiology physician affiliated with UPMC Central Pa. OpenAlex indexes 163 publications with 11,157 citations (h-index 36); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1000 N Front St
Wormleysburg, PA 170431021
Telephone
717-731-0101Provider last certified this registry record 2 Jan 2021.
Clinical trials
- Evaluation of Safety and Effectiveness of the EMBLOK EPS During TAVR
Sponsor: Emblok, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
14 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Medtronic, Inc.Program year2025135 payments$174,169openpaymentsdata.cms.gov ↗
- Abbott LaboratoriesProgram year202515 payments
- Boston Scientific CorporationProgram year202516 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
63%Beta blocker22%Metoprolol Succinate55%Metoprolol Tartrate38%Carvedilol7%Part D<11 patientsStatin10.9%Atorvastatin Calcium84%Rosuvastatin Calcium17%Part D<11 patients+ 9 more classes in this area
Blood & clotting
23.4%Factor Xa inhibitor10.4%Eliquis100%Part D≥20 patientsVitamin K antagonist7.3%Warfarin Sodium67%Jantoven33%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
11.7%SGLT2 inhibitor11.7%Jardiance100%Part D≥21 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- 5-Year Outcomes After Transcatheter or Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis
Journal of the American College of Cardiology
2025 - Self-Expanding or Balloon-Expandable TAVR in Patients with a Small Aortic Annulus
New England Journal of Medicine
2024 - Transcatheter Aortic-Valve Replacement for Asymptomatic Severe Aortic Stenosis
New England Journal of Medicine
2024
Similar KOLs
Other experts from the same institution or the same specialty.
David Weksberg, MD
UPMC Central Pa
William Beutler, MD
UPMC Central Pa
Mark Jarowenko, MD
UPMC Central Pa
Kit Lu, MD
UPMC Central Pa
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”